Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2008

01-07-2008 | Preclinical Study

Differential gene expression profile in breast cancer-derived stromal fibroblasts

Authors: Christian F. Singer, Daphne Gschwantler-Kaulich, Anneliese Fink-Retter, Cornelia Haas, Gernot Hudelist, Klaus Czerwenka, Ernst Kubista

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Login to get access

Abstract

Background

Breast cancer is characterized by malignant transformation of epithelial cells, but stromal cells also play an important role in tumorigenesis. While tumor-derived fibroblasts display unique phenotypic properties, it is unclear whether they also represent are a specific subpopulation.

Materials and Methods

Stromal fibroblasts deriving from malignant tissue of 10 women with invasive breast cancer, and from normal breast tissue of 10 women with benign breast disorders, were subjected to differential complementary DNA Microarray Analysis by using a 2,400 gene cDNA array. Individual gene expression pattern were confirmed by RT-PCR.

Results

In a cDNA array that allows to analyze the differential gene expression of more than 2,400 genes, the mRNA expression of 135 genes were increased more than 2 fold in fibroblasts from malignant breast tumors. The majority of these genes encode tumor-promoting cytokines, transcription factors and cell-matrix associated proteins. The mRNA expression of 110 genes decreased to less than 0.5 fold. The remaining 2,155 genes were not significantly altered. RT-PCR performed on individual biopsies from breast cancer and normal breast tissues confirmed the validity of the pooled gene expression signature.

Conclusion

Breast cancer-derived stromal fibroblasts show a distinctive gene expression pattern that differentiates them from normal breast stroma. Our observation of increased expression of tumor promotion-associated genes even in the absence of adjacent malignant epithelium suggests that tumor stroma is comprised of a fibroblastic subpopulation that provides for a microenvironment which supports tumor growth and invasion.
Literature
1.
go back to reference Wiseman BS, Werb Z (2002) Stromal effects on mammary gland development and breast cancer. Science 296:1046–1049PubMedCrossRef Wiseman BS, Werb Z (2002) Stromal effects on mammary gland development and breast cancer. Science 296:1046–1049PubMedCrossRef
2.
go back to reference Bonnette SG, Hadsell SL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–4945PubMedCrossRef Bonnette SG, Hadsell SL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–4945PubMedCrossRef
3.
go back to reference Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRef Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRef
4.
go back to reference Kucab JE, Dunn SE (2003) Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis 17:41–47PubMed Kucab JE, Dunn SE (2003) Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis 17:41–47PubMed
5.
go back to reference Derynck R, Akhurst JR, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129PubMedCrossRef Derynck R, Akhurst JR, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129PubMedCrossRef
6.
go back to reference Kaklamani V, Pasche B (2005) Transforming growth factor beta and breast cancer. Cancer Treat Res 126:129–156PubMedCrossRef Kaklamani V, Pasche B (2005) Transforming growth factor beta and breast cancer. Cancer Treat Res 126:129–156PubMedCrossRef
7.
go back to reference Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2(4):252–257PubMedCrossRef Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2(4):252–257PubMedCrossRef
8.
go back to reference Mercurio AM, Bachelder RE, Chung J, O’Connor KL, Rabinovitz I, Shaw LM, Tani T (2001) Integrin laminin receptors and breast carcinoma progression. J Mammary Gland Biol Neoplasia 6(3):299–309PubMedCrossRef Mercurio AM, Bachelder RE, Chung J, O’Connor KL, Rabinovitz I, Shaw LM, Tani T (2001) Integrin laminin receptors and breast carcinoma progression. J Mammary Gland Biol Neoplasia 6(3):299–309PubMedCrossRef
9.
go back to reference Torricelli C, Fortino V, Capurro E, Sacchi G, Ponzo P, Pacini A, Muscettola M, Maioli E (2006) Role of PTHrp and PTHrp-engaged pathways in MCF-7 cells migration/invasion. Matrix Biol 25(2):104–111PubMedCrossRef Torricelli C, Fortino V, Capurro E, Sacchi G, Ponzo P, Pacini A, Muscettola M, Maioli E (2006) Role of PTHrp and PTHrp-engaged pathways in MCF-7 cells migration/invasion. Matrix Biol 25(2):104–111PubMedCrossRef
10.
go back to reference Barcellos-Hoff MH, Medina D (2005) New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res 7(1):33–36PubMedCrossRef Barcellos-Hoff MH, Medina D (2005) New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res 7(1):33–36PubMedCrossRef
11.
go back to reference Kim JB, Stein R, O’Hare MJ (2005) Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26(4):173–185PubMedCrossRef Kim JB, Stein R, O’Hare MJ (2005) Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26(4):173–185PubMedCrossRef
12.
go back to reference Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ (1995) Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 55(11):2448–2454PubMed Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ (1995) Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 55(11):2448–2454PubMed
13.
go back to reference Grey AM, Schor AM, Rushton G, Ellis I, Schor SL (1989) Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts.Proc. Natl Acad Sci U S A 86:2438–2442CrossRef Grey AM, Schor AM, Rushton G, Ellis I, Schor SL (1989) Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts.Proc. Natl Acad Sci U S A 86:2438–2442CrossRef
14.
go back to reference Zrihan-Licht S, Lim J, Keydar I, Sliwkowski MX, Groopman JE, Avraham H (1997) Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells. J Biol Chem 272(3):1856–1863PubMedCrossRef Zrihan-Licht S, Lim J, Keydar I, Sliwkowski MX, Groopman JE, Avraham H (1997) Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells. J Biol Chem 272(3):1856–1863PubMedCrossRef
15.
go back to reference Gouon-Evans V, Rothenberg ME, Pollard JW (2000) Postnatal mammary gland development requires macrophages and eosinophils. Development 127(11):2269–2282PubMed Gouon-Evans V, Rothenberg ME, Pollard JW (2000) Postnatal mammary gland development requires macrophages and eosinophils. Development 127(11):2269–2282PubMed
16.
go back to reference Pollard JW, Hennighausen L (1994) Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc Natl Acad Sci U S A 91(20):9312–9316PubMedCrossRef Pollard JW, Hennighausen L (1994) Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc Natl Acad Sci U S A 91(20):9312–9316PubMedCrossRef
17.
go back to reference Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193(6):727–740PubMedCrossRef Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193(6):727–740PubMedCrossRef
18.
go back to reference Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25(9):857–862PubMedCrossRef Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25(9):857–862PubMedCrossRef
19.
go back to reference Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M (2001) Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757–2764PubMed Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M (2001) Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757–2764PubMed
20.
go back to reference Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 43(4):225–236PubMedCrossRef Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 43(4):225–236PubMedCrossRef
21.
go back to reference Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184(1):118–130PubMedCrossRef Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184(1):118–130PubMedCrossRef
22.
go back to reference Das R, Mahabeleshwar GH, Kundu GC (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278(31):28593–28606PubMedCrossRef Das R, Mahabeleshwar GH, Kundu GC (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278(31):28593–28606PubMedCrossRef
23.
go back to reference Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12(11 Pt 1):3337–3343PubMedCrossRef Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12(11 Pt 1):3337–3343PubMedCrossRef
24.
go back to reference Wakefield LM, Piek E, Bottinger EP (2001) TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6(1):67–82PubMedCrossRef Wakefield LM, Piek E, Bottinger EP (2001) TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6(1):67–82PubMedCrossRef
25.
go back to reference Muraoka-Cook RS, Dumont N, Arteaga CL (2005) Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 11(2 Pt 2):937s–943sPubMed Muraoka-Cook RS, Dumont N, Arteaga CL (2005) Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 11(2 Pt 2):937s–943sPubMed
26.
go back to reference Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147(3):631–644PubMedCrossRef Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147(3):631–644PubMedCrossRef
27.
go back to reference Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW (1999) Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 59(4):947–952PubMed Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW (1999) Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 59(4):947–952PubMed
Metadata
Title
Differential gene expression profile in breast cancer-derived stromal fibroblasts
Authors
Christian F. Singer
Daphne Gschwantler-Kaulich
Anneliese Fink-Retter
Cornelia Haas
Gernot Hudelist
Klaus Czerwenka
Ernst Kubista
Publication date
01-07-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9725-2

Other articles of this Issue 2/2008

Breast Cancer Research and Treatment 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine